A Phase 1 interventional study of Placebo and GSK2330811 in Healthy Volunteers, sponsored by GlaxoSmithKline. Completed at 1 site in United Kingdom. Open to male participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-05-24.
Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a randomized, double-blind (sponsor-open), placebo-controlled, single-center study involving Japanese participants. The purpose of the study is to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and immunogenicity after a single subcutaneous (SC) dose of GSK2330811 in healthy Japanese participants. GSK2330811 is a humanized immunoglobulin G1 (IgG1) monoclonal antibody that binds and inhibits the action of Oncostatin M (OSM) and is being developed for the treatment of Crohn's disease (CD) and Systemic sclerosis (SSc). Participants will be randomized to receive either GSK2330811 (450 milligram [mg]) or placebo in an approximate ratio of 7:3.
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a single 450 mg SC dose of GSK2330811, administered as three separate SC injections of 150 milligrams per milliliter \[mg/mL\]).
Drug: GSK2330811
Participants will receive GSK2330811 matching placebo administered as three separate SC injections.
Drug: Placebo
Placebo is 0.9 percent sodium chloride solution. It will be administered as SC injection to abdomen by study personnel. Three injections will be used to match active doses.
GSK2330811 will be available as SC injection 150 mg/mL.
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. A SAE is defined as any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment. Safety Population consisted of all randomized participants who received at least one dose of study treatment.
Time frame: Up to Day 126
Number of Participants With Worst Case Vital Sign Results Relative to Potential Clinical Importance (PCI) Criteria Post-Baseline Relative to Baseline
Vital signs were measured in semi-supine position after 5 minutes of rest and included systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate (HR). Participants were counted in the worst case category that their value changed to low, within range or high, unless there was no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became within range, were recorded in the "Within Range or No Change" category. Participants were counted twice if values changed 'To Low' and 'To High', so the percentages were not added up to 100 percent (%). Participants with missing Baseline values were assumed as within range value. PCI ranges were: SBP (lower: \<85, upper: \>160 millimeter of mercury \[mmHg\]); DBP (lower: \<45, upper: \>100 mmHg); HR (lower: \<40, upper: \>110 beats per minute). Baseline was defined as the pre-dose Day 1 assessment, unless unavailable, in which case it was the latest pre-dose assessment.
Time frame: Baseline (Pre-dose, Day 1) and up to Day 126
Change From Baseline in Body Temperature
Body temperature was measured in semi-supine position after 5 minutes of rest for the participants in a quiet setting without distractions. Baseline was defined as the pre-dose Day 1 assessment, unless unavailable, in which case it was the latest pre-dose assessment. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Pre-dose, Day 1), Day 1: 1, 4, 8 hours; Days 2, 3, 5, 7, 10, 14, 21, 28, 42, 56, 84 and 126
Number of Participants With Worst Case Abnormal Electrocardiogram (ECG) Findings
12-lead ECGs were recorded in semi-supine position using an ECG machine. Number of participants with worst-case clinically significant and not clinically significant abnormal ECG findings have been presented. Clinically significant abnormal laboratory findings were those which were not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.
Time frame: Up to Day 126
Number of Participants With Maximum Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 or Higher Clinical Chemistry Parameters
Blood samples were collected for the analysis of clinical chemistry parameters. Clinical chemistry parameters were summarized according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 5.0: Grade 1: mild; Grade 2: moderate; Grade 3: severe; Grade 4: life-threatening or disabling. Higher grade indicates more severity. Clinical chemistry parameters included: total bilirubin, calcium, creatinine and triglycerides.
Time frame: Up to Day 126
Number of Participants With Grade Increase Post-Baseline Relative to Baseline in Hematology Parameters
Blood samples were collected for the analysis of the following hematology parameters: hemoglobin (Hb), lymphocytes (Lympho), platelet count (PC), neutrophil count (Neutro) and White Blood Cell count (WBC). The laboratory parameters were graded according to NCI-CTCAE version 5.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. Higher grade indicates more severity. Baseline was defined as the pre-dose Day 1 assessment, unless unavailable, in which case it was the latest pre-dose assessment. An increase was defined as an increase in CTCAE Grade relative to Baseline Grade.
Time frame: Baseline (Pre-dose, Day 1) and up to Day 126
Number of Participants With Worst Case Any Increase in Urinalysis Results Post-Baseline Relative to Baseline
Urine samples were collected for analysis of blood, glucose, ketones and protein by a dipstick method. The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameters of urine glucose, protein, blood and ketones can be read as negative (-), trace, 1+, 2+, 3+ indicating proportional concentrations in the urine sample. Baseline was defined as the pre-dose Day 1 assessment, unless unavailable, in which case it was the latest pre-dose assessment. Any increase means any increase to trace, 1+, 2+ or 3+ post-Baseline relative to Baseline. Number of participants with worst case any increase in urinalysis results post-Baseline relative to Baseline has been presented.
Time frame: Baseline (Pre-dose, Day 1) and up to Day 126
Maximum Plasma Concentration (Cmax) for GSK2330811
Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of GSK2330811. PK parameters were calculated using standard non-compartmental analysis. Pharmacokinetic Population consisted of all participants in the Safety population who received at least one active dose of study treatment and had at least 1 non-missing PK assessment.
Time frame: Day 1: Pre-dose, 8 hours; Days 2, 3, 5, 7, 10, 14, 21, 28, 42, 56, 84 and 126
Area Under the Plasma Concentration Time-curve From Time Zero to Infinity (AUC[0-infinity]) for GSK2330811
Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2330811. PK parameters were calculated using standard non-compartmental analysis.
Time frame: Day 1: Pre-dose, 8 hours; Days 2, 3, 5, 7, 10, 14, 21, 28, 42, 56, 84 and 126
Area Under the Plasma Concentration-time Curve From Time Zero to the Time of Last Quantifiable Concentration (AUC[0-t]) for GSK2330811
Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2330811. PK parameters were calculated using standard non-compartmental analysis.
Time frame: Day 1: Pre-dose, 8 hours; Days 2, 3, 5, 7, 10, 14, 21, 28, 42, 56, 84 and 126
Apparent Systemic Clearance (CL/F) for GSK2330811
Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2330811. PK parameters were calculated using standard non-compartmental analysis.
Time frame: Day 1: Pre-dose, 8 hours; Days 2, 3, 5, 7, 10, 14, 21, 28, 42, 56, 84 and 126
Time to Cmax (Tmax) for GSK2330811
Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2330811. PK parameters were calculated using standard non-compartmental analysis.
Time frame: Day 1: Pre-dose, 8 hours; Days 2, 3, 5, 7, 10, 14, 21, 28, 42, 56, 84 and 126
Terminal Half-life (t1/2) for GSK2330811
Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2330811. PK parameters were calculated using standard non-compartmental analysis.
Time frame: Day 1: Pre-dose, 8 hours; Days 2, 3, 5, 7, 10, 14, 21, 28, 42, 56, 84 and 126
Apparent Volume of Distribution at Steady State (Vss/F) for GSK2330811
Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2330811. PK parameters were calculated using standard non-compartmental analysis.
Time frame: Day 1: Pre-dose, 8 hours; Days 2, 3, 5, 7, 10, 14, 21, 28, 42, 56, 84 and 126
Number of Participants With Positive Anti-GSK2330811 Antibodies
Serum samples were analyzed for the presence of anti-GSK2330811 antibodies using an antibody binding assay. The assay involved screening, confirmation and titration steps. If serum samples tested positive in the screening assay, they were considered 'potentially positive' and were further analyzed for the specificity using the confirmation assay. Number of participants with confirmed positive anti-GSK2330811 antibodies are presented.
Time frame: Up to Day 126
Platelet Count Nadir for GSK2330811
Blood samples were collected at indicated time points for analysis of platelet count nadir for GSK2330811. Nadir was defined as the lowest post-Baseline value of the platelet count.
Time frame: Days 1, 2, 3, 5, 7, 10, 14, 21, 28, 42, 56, 84 and 126
Time to Platelet Count Nadir for GSK2330811
Blood samples were collected at indicated time points for analysis of platelet count nadir for GSK2330811. Nadir was defined as the lowest post-Baseline value of the platelet count. Time to nadir was defined as Study Day of Nadir minus 1.
Time frame: Days 1, 2, 3, 5, 7, 10, 14, 21, 28, 42, 56, 84 and 126
Hemoglobin Nadir for GSK2330811
Blood samples were collected at the indicated time points for analysis of hemoglobin nadir for GSK2330811. Nadir was defined as the lowest post-Baseline value of the hemoglobin.
Time frame: Days 1, 2, 3, 5, 7, 10, 14, 21, 28, 42, 56, 84 and 126
Time to Hemoglobin Nadir for GSK2330811
Blood samples were collected at indicated time points for analysis of hemoglobin nadir for GSK2330811. Nadir was defined as the lowest post-Baseline value of the hemoglobin. Time to nadir was defined as Study Day of Nadir minus 1.
Time frame: Days 1, 2, 3, 5, 7, 10, 14, 21, 28, 42, 56, 84 and 126
This was a randomized, double-blind, placebo-controlled, single-center study with single subcutaneous (SC) dose of GSK2330811 administered in healthy male Japanese participants.
| Milestone | Placebo | GSK2330811 450 mg |
|---|---|---|
| Started | 2 | 7 |
| Completed | 2 | 6 |
| Not completed | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. A SAE is defined as any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment. Safety Population consisted of all randomized participants who received at least one dose of study treatment.
| Participants | Placebo | GSK2330811 450 mg |
|---|---|---|
| AEs | 2 | 6 |
| SAEs | 0 | 0 |
Vital signs were measured in semi-supine position after 5 minutes of rest and included systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate (HR). Participants were counted in the worst case category that their value changed to low, within range or high, unless there was no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became within range, were recorded in the "Within Range or No Change" category. Participants were counted twice if values changed 'To Low' and 'To High', so the percentages were not added up to 100 percent (%). Participants with missing Baseline values were assumed as within range value. PCI ranges were: SBP (lower: \<85, upper: \>160 millimeter of mercury \[mmHg\]); DBP (lower: \<45, upper: \>100 mmHg); HR (lower: \<40, upper: \>110 beats per minute). Baseline was defined as the pre-dose Day 1 assessment, unless unavailable, in which case it was the latest pre-dose assessment.
| Participants | Placebo | GSK2330811 450 mg |
|---|---|---|
| SBP, To low | 0 | 0 |
| SBP, To Within Range or No Change | 2 | 7 |
| SBP, To high | 0 | 0 |
| DBP, To low | 0 | 0 |
| DBP, To Within Range or No Change | 2 | 7 |
| DBP, To high | 0 | 0 |
| HR, To low | 0 | 0 |
| HR, To Within Range or No Change | 2 | 7 |
| HR, To high | 0 | 0 |
Body temperature was measured in semi-supine position after 5 minutes of rest for the participants in a quiet setting without distractions. Baseline was defined as the pre-dose Day 1 assessment, unless unavailable, in which case it was the latest pre-dose assessment. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| Degrees Celsius | Placebo | GSK2330811 450 mg |
|---|---|---|
| Day 1: 1 hour, n=2,7 | 0.15 ± 0.212 | 0.06 ± 0.237 |
| Day 1: 4 hour, n=2,7 | 0.40 ± 0.283 | 0.07 ± 0.287 |
| Day 1: 8 hour, n=2,7 | 0.45 ± 0.071 | 0.40 ± 0.346 |
| Day 2: n=2,7 | -0.15 ± 0.919 | -0.03 ± 0.486 |
| Day 3: n=2,7 | -0.30 ± 0.283 | -0.34 ± 0.336 |
| Day 5: n=2,7 | 0.20 ± 0.424 | -0.06 ± 0.800 |
| Day 7: n=2,7 | -0.30 ± 0.566 | 0.09 ± 0.521 |
| Day 10: n=2,7 | -0.10 ± 0.283 | -0.10 ± 0.862 |
| Day 14: n=2,7 | 0.25 ± 0.495 | 0.21 ± 0.537 |
| Day 21: n=2,7 | 0.05 ± 0.212 | 0.09 ± 0.609 |
| Day 28: n=2,7 | 0.20 ± 0.424 | -0.06 ± 0.670 |
| Day 42: n=2,7 | -0.60 ± 0.283 | -0.10 ± 0.695 |
| Day 56: n=2,6 | 0.00 ± 0.141 | -0.03 ± 0.715 |
| Day 84: n=1,6 | 0.90 ± NA | 0.30 ± 0.494 |
| Day 126: n=0,6 | — | 0.28 ± 0.595 |
12-lead ECGs were recorded in semi-supine position using an ECG machine. Number of participants with worst-case clinically significant and not clinically significant abnormal ECG findings have been presented. Clinically significant abnormal laboratory findings were those which were not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.
| Participants | Placebo | GSK2330811 450 mg |
|---|---|---|
| Abnormal - not clinically significant | 0 | 1 |
| Abnormal - clinically significant | 0 | 0 |
Blood samples were collected for the analysis of clinical chemistry parameters. Clinical chemistry parameters were summarized according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 5.0: Grade 1: mild; Grade 2: moderate; Grade 3: severe; Grade 4: life-threatening or disabling. Higher grade indicates more severity. Clinical chemistry parameters included: total bilirubin, calcium, creatinine and triglycerides.
| Participants | Placebo | GSK2330811 450 mg |
|---|---|---|
| Total Bilirubin, Grade 1 | 0 | 1 |
| Total Bilirubin, Grade 2 | 0 | 0 |
| Total Bilirubin, Grade 3 | 0 | 0 |
| Total Bilirubin, Grade 4 | 0 | 0 |
| Calcium, Grade 1 | 2 | 5 |
| Calcium, Grade 2 | 0 | 0 |
| Calcium, Grade 3 | 0 | 0 |
| Calcium, Grade 4 | 0 | 0 |
| Creatinine, Grade 1 | 0 | 1 |
| Creatinine, Grade 2 | 0 | 0 |
| Creatinine, Grade 3 | 0 | 0 |
| Creatinine, Grade 4 | 0 | 0 |
| Triglycerides, Grade 1 | 0 | 1 |
| Triglycerides, Grade 2 | 0 | 0 |
| Triglycerides, Grade 3 | 0 | 0 |
| Triglycerides, Grade 4 | 0 | 0 |
Blood samples were collected for the analysis of the following hematology parameters: hemoglobin (Hb), lymphocytes (Lympho), platelet count (PC), neutrophil count (Neutro) and White Blood Cell count (WBC). The laboratory parameters were graded according to NCI-CTCAE version 5.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. Higher grade indicates more severity. Baseline was defined as the pre-dose Day 1 assessment, unless unavailable, in which case it was the latest pre-dose assessment. An increase was defined as an increase in CTCAE Grade relative to Baseline Grade.
| Participants | Placebo | GSK2330811 450 mg |
|---|---|---|
| Hb, Anemia, increase to Grade 1 | 0 | 0 |
| Hb, Anemia, increase to Grade 2 | 0 | 0 |
| Hb, Anemia, increase to Grade 3 | 0 | 0 |
| Hb, Anemia, increase to Grade 4 | 0 | 0 |
| Hb, Hb increased, increase to Grade 1 | 0 | 0 |
| Hb, Hb increased, increase to Grade 2 | 0 | 0 |
| Hb, Hb increased, increase to Grade 3 | 0 | 0 |
| Hb, Hb increased, increase to Grade 4 | 0 | 0 |
| Lympho,Lympho count decreased, increase to Grade 1 | 0 | 3 |
| Lympho,Lympho count decreased, increase to Grade 2 | 1 | 0 |
| Lympho,Lympho count decreased, increase to Grade 3 | 0 | 0 |
| Lympho,Lympho count decreased, increase to Grade 4 | 0 | 0 |
| Lympho,Lympho count increased, increase to Grade 1 | 0 | 0 |
| Lympho,Lympho count increased, increase to Grade 2 | 0 | 0 |
| Lympho,Lympho count increased, increase to Grade 3 | 0 | 0 |
| Lympho,Lympho count increased, increase to Grade 4 | 0 | 0 |
| PC, PC decreased,increase to Grade 1 | 0 | 3 |
| PC, PC decreased,increase to Grade 2 | 0 | 2 |
| PC, PC decreased,increase to Grade 3 | 0 | 1 |
| PC, PC decreased,increase to Grade 4 | 0 | 0 |
| Neutro,Neutro count decreased,increase to Grade 1 | 0 | 0 |
| Neutro,Neutro count decreased,increase to Grade 2 | 0 | 1 |
| Neutro,Neutro count decreased,increase to Grade 3 | 0 | 0 |
| Neutro,Neutro count decreased,increase to Grade 4 | 0 | 0 |
| WBC,Leukocytosis, increase to Grade 1 | 0 | 0 |
| WBC,Leukocytosis, increase to Grade 2 | 0 | 0 |
| WBC,Leukocytosis, increase to Grade 3 | 0 | 0 |
| WBC,Leukocytosis, increase to Grade 4 | 0 | 0 |
| WBC,WBC decreased, increase to Grade 1 | 0 | 0 |
| WBC,WBC decreased, increase to Grade 2 | 0 | 1 |
| WBC,WBC decreased, increase to Grade 3 | 0 | 0 |
| WBC,WBC decreased, increase to Grade 4 | 0 | 0 |
Urine samples were collected for analysis of blood, glucose, ketones and protein by a dipstick method. The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameters of urine glucose, protein, blood and ketones can be read as negative (-), trace, 1+, 2+, 3+ indicating proportional concentrations in the urine sample. Baseline was defined as the pre-dose Day 1 assessment, unless unavailable, in which case it was the latest pre-dose assessment. Any increase means any increase to trace, 1+, 2+ or 3+ post-Baseline relative to Baseline. Number of participants with worst case any increase in urinalysis results post-Baseline relative to Baseline has been presented.
| Participants | Placebo | GSK2330811 450 mg |
|---|---|---|
| Blood | 1 | 1 |
| Glucose | 0 | 0 |
| Ketones | 0 | 1 |
| Protein | 1 | 2 |
Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of GSK2330811. PK parameters were calculated using standard non-compartmental analysis. Pharmacokinetic Population consisted of all participants in the Safety population who received at least one active dose of study treatment and had at least 1 non-missing PK assessment.
| Nanogram per milliliter | GSK2330811 450 mg |
|---|---|
| Maximum Plasma Concentration (Cmax) for GSK2330811 | 63259.308 ± 14.9290 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2330811. PK parameters were calculated using standard non-compartmental analysis.
| Hours*nanogram per milliliter | GSK2330811 450 mg |
|---|---|
| Area Under the Plasma Concentration Time-curve From Time Zero to Infinity (AUC[0-infinity]) for GSK2330811 | 45371065.201 ± 22.1925 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2330811. PK parameters were calculated using standard non-compartmental analysis.
| Hours*nanogram per milliliter | GSK2330811 450 mg |
|---|---|
| Area Under the Plasma Concentration-time Curve From Time Zero to the Time of Last Quantifiable Concentration (AUC[0-t]) for GSK2330811 | 43157791.065 ± 22.8839 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2330811. PK parameters were calculated using standard non-compartmental analysis.
| Liter per hour | GSK2330811 450 mg |
|---|---|
| Apparent Systemic Clearance (CL/F) for GSK2330811 | 0.010 ± 22.1925 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2330811. PK parameters were calculated using standard non-compartmental analysis.
| Hours | GSK2330811 450 mg |
|---|---|
| Time to Cmax (Tmax) for GSK2330811 | 143.380 (94.82 to 216.25) |
Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2330811. PK parameters were calculated using standard non-compartmental analysis.
| Hours | GSK2330811 450 mg |
|---|---|
| Terminal Half-life (t1/2) for GSK2330811 | 469.117 ± 14.8081 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK2330811. PK parameters were calculated using standard non-compartmental analysis.
| Liter | GSK2330811 450 mg |
|---|---|
| Apparent Volume of Distribution at Steady State (Vss/F) for GSK2330811 | 6.713 ± 12.2891 |
Serum samples were analyzed for the presence of anti-GSK2330811 antibodies using an antibody binding assay. The assay involved screening, confirmation and titration steps. If serum samples tested positive in the screening assay, they were considered 'potentially positive' and were further analyzed for the specificity using the confirmation assay. Number of participants with confirmed positive anti-GSK2330811 antibodies are presented.
| Participants | Placebo | GSK2330811 450 mg |
|---|---|---|
| Number of Participants With Positive Anti-GSK2330811 Antibodies | 0 | 0 |
Blood samples were collected at indicated time points for analysis of platelet count nadir for GSK2330811. Nadir was defined as the lowest post-Baseline value of the platelet count.
| Giga cells per liter | Placebo | GSK2330811 450 mg |
|---|---|---|
| Platelet Count Nadir for GSK2330811 | 211.5 ± 27.58 | 79.1 ± 29.48 |
Blood samples were collected at indicated time points for analysis of platelet count nadir for GSK2330811. Nadir was defined as the lowest post-Baseline value of the platelet count. Time to nadir was defined as Study Day of Nadir minus 1.
| Days | Placebo | GSK2330811 450 mg |
|---|---|---|
| Time to Platelet Count Nadir for GSK2330811 | 44.0 (4 to 84) | 20.0 (20 to 26) |
Blood samples were collected at the indicated time points for analysis of hemoglobin nadir for GSK2330811. Nadir was defined as the lowest post-Baseline value of the hemoglobin.
| Grams per liter | Placebo | GSK2330811 450 mg |
|---|---|---|
| Hemoglobin Nadir for GSK2330811 | 136.0 ± 8.49 | 134.9 ± 6.69 |
Blood samples were collected at indicated time points for analysis of hemoglobin nadir for GSK2330811. Nadir was defined as the lowest post-Baseline value of the hemoglobin. Time to nadir was defined as Study Day of Nadir minus 1.
| Days | Placebo | GSK2330811 450 mg |
|---|---|---|
| Time to Hemoglobin Nadir for GSK2330811 | 30.5 (20 to 41) | 55.0 (14 to 125) |
Collected over All-cause mortality, SAEs and non SAEs were collected up to Day 126. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/2 (0%) | 0/2 (0%) | 2/2 (100%) |
| GSK2330811 450 mg | 0/7 (0%) | 0/7 (0%) | 6/7 (85.7%) |
| Event | Placebo | GSK2330811 450 mg |
|---|---|---|
| ThrombocytopeniaBlood and lymphatic system disorders | 0/2 | 5/7 |
| Arthropod biteInjury, poisoning and procedural complications | 1/2 | 0/7 |
| Face injuryInjury, poisoning and procedural complications | 1/2 | 0/7 |
| Injection site painGeneral disorders | 1/2 | 0/7 |
| NasopharyngitisInfections and infestations | 1/2 | 0/7 |
| Oral herpesInfections and infestations | 1/2 | 0/7 |
| Skin lacerationInjury, poisoning and procedural complications | 0/2 | 1/7 |
| Abdominal painGastrointestinal disorders | 0/2 | 1/7 |
| Mouth ulcerationGastrointestinal disorders | 0/2 | 1/7 |
| Injection site bruisingGeneral disorders | 0/2 | 1/7 |
| Age, Continuous(Years) | Placebo | GSK2330811 450 mg | Total |
|---|---|---|---|
| Mean | 21.0 ± 2.83 | 29.1 ± 6.52 | 27.3 ± 6.76 |
| Sex: Female, Male(Participants) | Placebo | GSK2330811 450 mg | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 2 | 7 | 9 |
| Race/Ethnicity, Customized(Participants) | Placebo | GSK2330811 450 mg | Total |
|---|---|---|---|
| Asian - Japanese Heritage | 2 | 7 | 9 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · clinicalstudydatarequest.com
Ran from Dec 2019 to primary completion in May 2020, 5 months.
Results were first posted in May 2021, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: GSK-2330811